Porphyria Cutanea Tarda (PCT)
The most common porphyria, marked by fragile, blistering skin on sun-exposed areas and closely linked to liver enzyme deficiency, iron overload, and triggers like hepatitis C and alcohol.
- Trigger identification support
- Iron status evaluation
- Liver health coordination
- Most Common Porphyria
- ~1 in 10,000ā25,000
- Typical Onset
- Adulthood (40sā60s)
- Primary Gene/Enzyme
- UROD (Uroporphyrinogen Decarboxylase)
- Key Treatment
- Therapeutic Phlebotomy
Condition Overview
Porphyria Cutanea Tarda (PCT) is the most common type of porphyria and results from reduced activity of uroporphyrinogen decarboxylase (UROD), an enzyme in the heme synthesis pathway. Reduced UROD activity allows porphyrins to build up in the liver and skin, leading to fragile skin that blisters with minor trauma or sun exposure.
Unlike some porphyrias that are purely genetic, PCT is frequently triggered or worsened by acquired factors such as excess iron, alcohol use, estrogen therapy, hepatitis C infection, and HIV. Identifying and addressing these triggers, alongside treatments like therapeutic phlebotomy, often leads to significant and lasting improvement.
Types and Subtypes
PCT is classified by whether the UROD deficiency is confined to the liver or also present in other tissues, and whether it is inherited.
Symptoms and Signs
PCT primarily affects sun-exposed, trauma-prone skin and can be accompanied by signs of underlying liver dysfunction.
Causes and Risk Factors
PCT develops when reduced UROD enzyme activity combines with one or more acquired factors that further stress the heme pathway and promote iron accumulation in the liver.
Diagnosis and Investigations
Diagnosis relies on characteristic skin findings confirmed with urine, plasma, and stool porphyrin testing, along with a search for underlying triggers.
Disease Severity and Risk Stratification
PCT severity is generally stratified by extent of skin involvement and degree of hepatic injury rather than a formal staging system.
Standard Treatment Options
PCT is one of the more treatable porphyrias: removing triggers and reducing hepatic iron typically produce marked clinical improvement.
Advanced & Emerging Therapies
Most PCT responds well to standard measures, but persistent or treatment-resistant cases may benefit from further evaluation.
Iron Chelation
Iron chelation therapy
Considered in select patients who cannot tolerate phlebotomy, to reduce hepatic iron burden.
Antiviral Therapy
Direct-acting antivirals for hepatitis C
Clearing hepatitis C infection, when present, can substantially improve PCT activity.
Hepatology Co-Management
Specialist liver disease monitoring
For patients with advanced fibrosis, coordinated hepatology follow-up including surveillance for liver complications.
Biomarkers & Precision Medicine
Biomarker testing both confirms PCT and identifies the acquired factors driving disease activity.
When a Second Opinion May Be Important
A specialist opinion is particularly useful when triggers are unclear or initial treatment response is limited.
Clinical Trials and Research
Prognosis and Key Outcome Factors
PCT generally has a favorable prognosis when triggers are identified and removed, with most patients experiencing substantial improvement in skin symptoms.
Supportive Care and Living With PCT
Supportive measures help protect skin while underlying triggers and iron levels are addressed.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Porphyria Cutanea Tarda coordinate specialist review of liver and porphyrin test results and connect with hepatology and dermatology expertise for trigger management.
Get a free case reviewFrequently Asked Questions
It is the most common porphyria, causing fragile, blistering skin due to reduced activity of the UROD enzyme in heme production.
Common triggers include excess alcohol use, estrogen-containing medications, hepatitis C infection, HIV, and iron overload.
Most cases are sporadic and acquired, but a familial form caused by an inherited UROD mutation also exists.
Therapeutic phlebotomy to reduce iron stores and low-dose antimalarial medication are the main treatments, alongside removing identifiable triggers.
Yes, PCT is associated with increased risk of liver fibrosis and cirrhosis, so liver monitoring is an important part of care.
Hepatitis C is one of the most frequently identified triggers, and treating the infection often improves PCT.
It typically causes blisters, fragile skin, and slow-healing erosions on sun-exposed areas like the hands and face.
Diagnosis is confirmed with elevated urine and plasma porphyrin levels along with screening for underlying triggers.
PCT can often be put into long-term remission by removing triggers and reducing iron stores, though monitoring for recurrence is reasonable.
Yes. CancerFax can help you organize porphyrin and liver test results for specialist review, coordinate a second opinion, and connect you with hepatology and dermatology specialists experienced in PCT management.
Considering a Specialist Review for PCT?
Send your porphyrin and liver panel results so a specialist can help identify triggers and refine your treatment plan.